ITC General Exclusion Order on tirzepatide
This is one entry from the TitrateLab Vendor Graveyard, a dated, primary-source archive of peptide-market shutdowns, exit scams, and enforcement actions. Documented as April 15, 2025. Sources for this entry are named inline below and numbered in full on the parent archive page.
The US International Trade Commission’s Section 337 Commission determination found that tirzepatide respondents had violated the statute by importing infringing products. The General Exclusion Order gave Customs and Border Protection standing authority to seize tirzepatide at ports of entry, without the case-by-case review that had previously slowed enforcement.
Why it still matters: first peptide-class GEO. Changed the math of Chinese-direct shipping for tirzepatide specifically, and, by extension, the risk profile for all GLP-1 imports. Customs seizures in Cincinnati alone surged in the quarters following this order.
Primary sources: Federal Register notice, April 15 2025; USITC Section 337 case file on Certain Tirzepatide Products.